Drug Trial Radar · NCT04586023
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
751
Actual
Start
Mar 24, 2021
Primary completion
Sep 5, 2025
Study completion Jul 9, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.
Conditions
- Relapsing Multiple Sclerosis
Interventions
FenebrutinibDrug
Participants will receive fenebrutinib.
TeriflunomideDrug
Participants will receive teriflunomide.
PlaceboDrug
Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: Minimum of 96 weeks
Locations
106 sites in 17 countries. Site status is shown where the registry gives one.
North Central Neurology Associates
Cullman, Alabama
Xenoscience
Phoenix, Arizona
Los Angeles Biomedical Research Institute at Harbor-UCLA
Torrance, California
Georgetown University Medical Center
Washington D.C., District of Columbia
University of South Florida
Tampa, Florida
American Health Network Institute, LLC
Avon, Indiana
University of Kansas Medical Center
Kansas City, Kansas
Neuro Institute of New England P.C.
Foxborough, Massachusetts
University of Cincinnati
Cincinnati, Ohio
Hope Neurology
Knoxville, Tennessee
Integrated Neurology Services PLLC
Falls Church, Virginia
Medical College of Wisconsin, Inc.
Milwaukee, Wisconsin
Kepler Universitätskliniken GmbH - Med Campus III
Linz, Austria
Jordy Sinapse Medicina LTDA ME
São Paulo, Brazil
L2 Ip Instituto de Pesquisas Clinicas Ltda ME
Brasília, Federal District, Brazil
Freire Pesquisa Clinica
Belo Horizonte, Minas Gerais, Brazil
Instituto de Neurologia de Curitiba
Curitiba, Paraná, Brazil
IMV Pesquisa Neurológica
Porto Alegre, Rio Grande do Sul, Brazil
Núcleo de Pesquisa do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Clinica Neurologica
Joinville, Santa Catarina, Brazil
Praxis Pesquisa Médica
Santo André, São Paulo, Brazil
CEMEC - Centro Multidisciplinar de Estudos Clínicos
São Bernardo do Campo, São Paulo, Brazil
Centro de Pesquisas Clinicas
São Paulo, São Paulo, Brazil
Hospital Santa Marcelina
São Paulo, São Paulo, Brazil
UMHAT Dr. Georgi Stranski
Pleven, Bulgaria
MHATNP Sveti Naum EAD
Sofia, Bulgaria
University of Alberta Hospital
Edmonton, Alberta, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi Hospital
Chicoutimi, Quebec, Canada
MUCH - Montreal Neurological Institute & Hospital
Montreal, Quebec, Canada
CHU de Québec
Québec, Quebec, Canada
Sydvestjysk Sygehus Esbjerg
Esbjerg, Denmark
Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken
Sønderborg, Denmark
Hopital Gabriel Montpied CHU de Clermont-Ferrand
Clermont-Ferrand, France
Hôpital Pasteur
Nice, France
Hôpital Charles Nicolle
Rouen, France
CHU toulouse - Hôpital Purpan
Toulouse, France
Hospital Eginition
Athens, Greece
University General Hospital of Larisa
Larissa, Greece
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.